← Back to Search

Monoclonal Antibodies

Briquilimab for Allergic Asthma

Phase 1
Waitlist Available
Research Sponsored by Jasper Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Men and women 18 to 65 years of age; stable, allergic asthma; history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline at least 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form; positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 \[PC20\] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg); and positive skin-prick test and positive allergen-induced early and late airway bronchoconstriction to common aeroallergens.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months)
Awards & highlights

Summary

Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.

Who is the study for?
This trial is for individuals with allergic asthma. Participants should be healthy enough to undergo an allergen challenge and have a confirmed diagnosis of allergic asthma. Specific details about age, previous treatments, or other health conditions that might affect eligibility are not provided.
What is being tested?
The study tests the safety and effectiveness of Briquilimab compared to a placebo in treating allergic asthma. It's a single-dose study where participants receive either Briquilimab or a placebo without knowing which one they get, to see how well the drug works.
What are the potential side effects?
Since this summary doesn't specify side effects, it can be assumed that potential side effects may include typical reactions seen in allergy and immunotherapy trials such as injection site reactions, headaches, fatigue, or respiratory symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants
Secondary study objectives
Comparison of allergen-induced inflammatory mediators at 7h and 24h post allergen, between briquilimab and placebo
Comparison of the allergen-induced changes in sputum leukocytes at 7h and 24h post allergen challenge, between the briquilimab and placebo.
Comparison of the allergen-induced shift in AHR to methacholine at 24 hours after the allergen challenge, between briquilimab and placebo.
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BriquilimabExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Jasper Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
180 Total Patients Enrolled
~20 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top